Core Viewpoint - OptiNose (OPTN) shares surged 52.5% following the announcement of its acquisition by Paratek Pharmaceuticals, which will enhance Paratek's commercial portfolio with OptiNose's approved product, Xhance [1] Company Overview - Xhance is a drug-device therapy for chronic rhinosinusitis (CRS), utilizing a proprietary Exhalation Delivery System to deliver corticosteroids directly to inflammation sites, improving patient outcomes and potentially reducing the need for invasive treatments [2] - The acquisition allows OptiNose to expand Xhance's market reach, addressing challenges in adoption, with Paratek's commercial infrastructure enhancing awareness among primary care providers [3][4] Market Potential - Xhance's label was expanded in 2024 to include CRS without nasal polyps, increasing its market potential nearly tenfold by incorporating primary care providers into its prescriber base [5] - Xhance is now the only approved therapy for CRS patients regardless of nasal polyp status, addressing significant unmet clinical needs [6] Financial Details - Paratek will acquire all outstanding shares of OptiNose for $9 per share in cash, with an additional potential $5 per share based on revenue milestones for Xhance, totaling a deal value of up to $330 million [8] - The upfront cash payment represents a 50% premium over OptiNose's closing share price on March 19, 2025 [8] Transaction Timeline - The acquisition is expected to be completed in mid-2025, pending customary and regulatory closing conditions [9]